Pfizer has raised its profit outlook for 2025, citing successful cost-cutting measures and robust quarterly financial results. The pharmaceutical giant's announcement arrives amidst industry-wide challenges, including potential impacts from former President Trump's proposals to reduce U.S. drug prices and his threatened tariffs on pharmaceutical imports. The company is navigating a complex economic and political landscape while aiming to maintain profitability and growth.